Original Article
Copyright ©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 21, 2011; 17(43): 4779-4786
Published online Nov 21, 2011. doi: 10.3748/wjg.v17.i43.4779
Figure 3
Figure 3 Progression-free survival of advanced colorectal cancer patients with KRAS wild type and patients with KRAS mutation treated by cetuximab-containing chemotherapy. Thirty-seven of 45 patients were successfully tested KRAS gene in cetuximab-containing chemotherapy group, the median PFS of patients with KRAS wild type was significantly higher than that of patients with KRAS mutation ( 5.0 mo and 2.5 mo, respectively, P = 0.02). PFS: Progression-free survival.